Clinical trials: Treatment Resistant
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA
The purpose of this study is to assess the strategy in treatment selection using ctDNA fraction as a predictive biomarker to direct treatment decision (ctDNA fraction <2% receives enzalutamide, and ctDNA fraction ≥2% receives…
- Trial name
- PROTRACT (NCT04015622)
- Testing
- Enzalutamide, Docetaxel
- Where
- 7 sites in Canada
- Volunteers
- 100 people
- Sponsor
- British Columbia Cancer Agency
Small Cell Lung Cancer
Transformation Into Small Cell Lung Cancer : a Mode of Resistance to Treatment
The discovery of oncogenic mutations and the use of targeted therapies have transformed the management of certain tumors. Thus 12 to 15% of bronchial adenocarcinomas (AD) carry mutations of EGFR and receive from the first line…
- Trial name
- TransCPC (NCT03419286)
- Volunteers
- 62 people
- Sponsor
- University Hospital, Grenoble
Epilepsy
A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures
This is a multicentre, long-term, open-label extension (OLE) study to assess the long-term safety, tolerability and efficacy of retigabine immediate-release (IR) as adjunctive therapy in adult Asian subjects with drug-resistant…
- Trial name
- NCT01777139
- Testing
- Retigabine IR
- Where
- 12 sites in Malaysia, South Korea and 1 more
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Gestational Diabetes
Myoinositol Supplementation, Insulin Resistance and Fetal Sonographic Parameters in Gestational Diabetes Diet Treated
The aim of this study is to verify the beneficial effects on insulin resistance and fetal sonographic parameters of a diet supplementation of myoinositol taken during the third trimester by pregnant women affected by gestational…
- Trial name
- MYOGDM (NCT03763669)
- Testing
- Myoinositol
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- University of Messina
Infection, Human Immunodeficiency Virus
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection
This 48 week, phase 2b study in 150 HIV-1 infected antiretroviral therapy experienced adult subjects consists of a dose-ranging evaluation of GSK2248761 at blinded doses of 100 mg and 200 mg once daily with a control arm of…
- Trial name
- SONNET (NCT01199731)
- Testing
- GSK2248761 100 mg once daily, GSK2248761 200 mg once daily, Etravirine
- Where
- 41 sites in United States, Belgium and 3 more
- Volunteers
- 30 people
- Sponsor
- ViiV Healthcare
Chronic Hepatitis B - Antiviral Drug Resistance - Hepatitis B Virus (HBV) Infection
Prevalence and Risk Factors of Antiviral Resistance in Egyptian HBV Patients
This study aims to determine the prevalence of antiviral drug resistance among Egyptian patients with chronic hepatitis B virus (HBV) infection and to identify the associated demographic, clinical, and virological risk factors.
- Trial name
- PRARE-CHB (NCT07274345)
- Volunteers
- 2,000 people
- Sponsor
- Amira Mohamed Zidan
Endometrial Neoplasms, Endometrial Cancer
Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia
This is a single-center, randomized, open-label, controlled clinical trial evaluating whether adding orlistat to standard progestin therapy can improve treatment response in patients receiving fertility-sparing treatment for…
- Conditions
- Endometrial Neoplasms, Endometrial Cancer, Atypical Endometrial Hyperplasia, Progestin Resistance
- Trial name
- PKUPH-ORLPP-EC (NCT07714070)
- Testing
- Orlistat, Progestin
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Peking University People's Hospital
Depressive Disorder
An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression
This study will examine whether a highly specific and powerful 5-hydroxytryptamine 2A (5-HT2A) antagonist, M100907, combined with escitalopram, is responsible for an antidepressant effect.
- Trial name
- NCT00070694
- Testing
- MDL100.907
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Institute of Mental Health (NIMH)
Chronic Hepatitis B
Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.
The purpose of this study is to determine the safety and antiviral HBV activity of ACH-126,443 (beta-L-Fd4C) in the treatment of Subjects of Previous Achillion-Sponsored Phase 1 and 2 Studies in Chronic Hepatitis B Infection.
- Trial name
- NCT00037622
- Testing
- ACH-126, 443 (beta-L-Fd4C)
- Volunteers
- 100 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
ATM Gene Mutation, BRCA1 Gene Mutation
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
This phase II trial studies how well docetaxel with carboplatin followed by rucaparib camsylate works in treating patients with metastatic castration resistant prostate cancer (spread outside of prostate and resistant to…
- Conditions
- ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Castration Levels of Testosterone
- Trial name
- NCT03442556
- Testing
- Carboplatin, Docetaxel, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Washington
Tinea Corporis, Dermatophytosis
Comparing the Efficacy of Oral Fluconazole Versus Oral Itraconazole in Treating Resistant Tinea Corporis
Tinea corporis (commonly called "ringworm of the body") is a skin infection caused by fungi that often becomes difficult to treat when it persists despite creams or other medicines.
- Trial name
- FIVIT (NCT07342153)
- Testing
- Itraconazole (200 mg), Fluconazole 150 mg
- Where
- Pakistan
- Volunteers
- 126 people
- Sponsor
- Urooj Fatima
Major Depression, Generalized Anxiety Disorder
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
The purpose of this study is to explore the changes in metabolic parameters in patients treated with escitalopram for six months for major depression, generalized anxiety disorder or panic disorder, with or without agoraphobia.
- Conditions
- Major Depression, Generalized Anxiety Disorder, Panic Disorder
- Trial name
- NCT00711737
- Where
- Singapore
- Volunteers
- 27 people
- Sponsor
- Changi General Hospital
Treatment Resistant Depression
An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression
An open-label, multi-centre, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamics of one and two doses of intranasal BPL-003 combined with psychological support, in patients with treatment resistant…
- Trial name
- NCT05660642
- Testing
- BPL-003
- Where
- 3 sites in United Kingdom
- Volunteers
- 72 people
- Sponsor
- Beckley Psytech Limited
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors
Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Phase I: Characterize safety and tolerability of ERW316 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation.
- Conditions
- Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Trial name
- NCT07570966
- Testing
- ERW316, Fulvestrant, Letrozole
- Sponsor
- Novartis Pharmaceuticals
Major Depressive Disorder, Depression
Buprenorphine Used With Treatment Resistant Depression in Older Adults
The investigators are conducting a research study to learn about the safety and benefit of using a medication called buprenorphine for patients with difficult to treat depression.
- Trial name
- IRLGreyB (NCT02181231)
- Testing
- venlafaxine XR, buprenorphine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Castration-resistant Prostate Cancer
Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to evaluate the effectiveness of Disitamab Vedotin in the treatment of subjects with locally advanced or metastatic castration-resistant prostate cancer.
- Trial name
- NCT06227156
- Testing
- Disitamab Vedotin Injection
- Where
- 3 sites in China
- Volunteers
- 40 people
- Sponsor
- RemeGen Co., Ltd.
HIV Infections
Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance
The goal of this study is to examine whether enfuvirtide (T20, Fuzeon) has continued anti-HIV activity in patients experiencing an incomplete virologic response to an enfuvirtide-based regimen.
- Trial name
- NCT00187551
- Testing
- Interruption of enfuvirtide, enfuvirtide interrupton
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, San Francisco
Prostate Cancer, Castration-Resistant Prostate Cancer
Testosterone Therapy in Castration Resistant Prostate Cancer
This is an open-labeled, single-arm, interventional pilot study. It is being done to determine the feasibility of the administration of transdermal testosterone alternating with enzalutamide, as well as the safety and efficacy.
- Trial name
- NCT03734653
- Testing
- Transdermal Testosterone, Standard of Care, Enzalutamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Colorado, Denver
Diabetes Mellitus, Type 2
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
The purpose of this study is to assess changes from baseline in insulin sensitivity, hepatic fat content and beta cell function after approximately 24-25 weeks of treatment with canagliflozin compared to placebo in participants…
- Trial name
- NCT02009488
- Testing
- Canagliflozin, 100 mg, Canagliflozin, 300 mg
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- Janssen Research & Development, LLC
Gonorrhea
New AntiBiotic Treatment Options for Uncomplicated Anogenital GOnorrhoea
This study evaluates the efficacy of three experimental antibiotics in the treatment of uncomplicated anogenital gonorrhoea. Participants will be randomized to one of four study arms and will receive either one of the three…
- Trial name
- NABOGO (NCT03294395)
- Testing
- Ertapenem 1000 MG, Fosfomycin Oral Suspension, Gentamicin Sulfate, Injectable
- Where
- Netherlands
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- Public Health Service of Amsterdam
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.